Daiichi Sankyo brings back old technology in new cancer venture
The medical industry is experiencing a revival of conjugated antibodies, which have also sparked Daiichi Sankyo’s ambitions of entering the cancer therapy market. The company’s global head of Oncology Development anticipates a glorious future for the technology.
The concept is quite simple. You combine an antibody with a cytotoxic agent to identify and kill cancer cells – sort of like a homing missile directed at cancer or, in a more technological terminology, an antibody drug conjugate (ADC).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
